Biodexa Pharmaceuticals annual net profit margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
Biodexa Pharmaceuticals Net Profit Margin Growth & History (BDRX)
Biodexa Pharmaceuticals's net profit margin was −1,858.01% for fiscal 2023.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −1,858.01% | −762.73 pp |
| 2022 | 2022-12-31 | −1,095.28% | −150.64 pp |
| 2021 | 2021-12-31 | −944.64% | +5524.46 pp |
| 2020 | 2020-12-31 | −6,469.10% | −4972.81 pp |
| 2019 | 2019-12-31 | −1,496.29% | −720.75 pp |
| 2018 | 2018-12-31 | −775.54% | +848.73 pp |
| 2017 | 2017-12-31 | −1,624.27% | −100.31 pp |
| 2016 | 2016-12-31 | −1,523.96% | −789.49 pp |
| 2015 | 2015-12-31 | −734.47% | — |
Biodexa Pharmaceuticals net profit margin trends
Over the last five fiscal years, Biodexa Pharmaceuticals's net profit margin decreased from −775.54% to −1,858.01%, a change of −1082.46 percentage points.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...